<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>åˆ¶è¯æ—¥æŠ¥ - 2026-01-22</title>
    <style>
        :root, [data-theme="minimal"] {
            --bg-primary: #ffffff;
            --bg-secondary: #f5f5f7;
            --text-primary: #1d1d1f;
            --text-secondary: #86868b;
            --accent: #0071e3;
            --accent-hover: #0077ed;
            --border: #d2d2d7;
            --card-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.05);
            --header-bg: transparent;
            --header-text: var(--text-primary);
        }

        [data-theme="pharma-blue"] {
            --bg-primary: #f0f4f8;
            --bg-secondary: #ffffff;
            --text-primary: #2d3748;
            --text-secondary: #718096;
            --accent: #2b6cb0;
            --accent-hover: #2c5282;
            --border: #e2e8f0;
            --card-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.1), 0 2px 4px -1px rgba(0, 0, 0, 0.06);
            --header-bg: linear-gradient(135deg, #1a365d 0%, #2b6cb0 100%);
            --header-text: #ffffff;
        }

        [data-theme="warm"] {
            --bg-primary: #faf8f5;
            --bg-secondary: #ffffff;
            --text-primary: #451a03;
            --text-secondary: #78716c;
            --accent: #d97706;
            --accent-hover: #b45309;
            --border: #e7e5e4;
            --card-shadow: 0 1px 3px 0 rgba(0, 0, 0, 0.1);
            --header-bg: transparent;
            --header-text: var(--text-primary);
        }

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "SF Pro Display", "SF Pro Text", "Helvetica Neue", "PingFang SC", "Microsoft YaHei", sans-serif;
            background: var(--bg-primary);
            color: var(--text-primary);
            line-height: 1.5;
            -webkit-font-smoothing: antialiased;
        }

        .container {
            max-width: 980px;
            margin: 0 auto;
            padding: 0 22px;
        }

        /* Header */
        header {
            padding: 80px 0 60px;
            text-align: center;
        }

        .logo {
            font-size: 48px;
            margin-bottom: 16px;
        }

        h1 {
            font-size: 48px;
            font-weight: 600;
            letter-spacing: -0.02em;
            margin-bottom: 8px;
        }

        .subtitle {
            font-size: 21px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        /* Stats */
        .stats-bar {
            display: flex;
            justify-content: center;
            gap: 48px;
            padding: 32px 0;
            margin: 40px 0;
            border-top: 1px solid var(--border);
            border-bottom: 1px solid var(--border);
        }

        .stat {
            text-align: center;
        }

        .stat-value {
            font-size: 32px;
            font-weight: 600;
            color: var(--text-primary);
        }

        .stat-label {
            font-size: 14px;
            color: var(--text-secondary);
            margin-top: 4px;
        }

        /* Analysis Section */
        .analysis {
            background: var(--bg-secondary);
            border-radius: 18px;
            padding: 32px;
            margin-bottom: 48px;
        }

        .analysis h2 {
            font-size: 24px;
            margin-bottom: 16px;
        }

        .analysis-content {
            font-size: 17px;
            line-height: 1.7;
            color: var(--text-secondary);
        }

        /* Category Section */
        .category {
            margin-bottom: 56px;
        }

        .category-header {
            display: flex;
            align-items: baseline;
            gap: 12px;
            margin-bottom: 24px;
            padding-bottom: 12px;
            border-bottom: 1px solid var(--border);
        }

        .category-title {
            font-size: 28px;
            font-weight: 600;
        }

        .category-title-en {
            font-size: 17px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        .category-count {
            background: var(--bg-secondary);
            color: var(--text-secondary);
            padding: 4px 12px;
            border-radius: 20px;
            font-size: 14px;
            margin-left: auto;
        }

        /* News Card */
        .news-card {
            background: var(--bg-primary);
            border: 1px solid var(--border);
            border-radius: 18px;
            padding: 28px;
            margin-bottom: 16px;
            transition: all 0.3s ease;
        }

        .news-card:hover {
            box-shadow: var(--card-shadow);
            transform: translateY(-2px);
        }

        .news-card h3 {
            font-size: 21px;
            font-weight: 600;
            margin-bottom: 12px;
            line-height: 1.4;
        }

        .news-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 16px;
            margin-bottom: 16px;
            font-size: 14px;
            color: var(--text-secondary);
        }

        .news-source {
            color: var(--accent);
            font-weight: 500;
        }

        .news-importance {
            letter-spacing: 2px;
        }

        .news-summary {
            font-size: 17px;
            color: var(--text-secondary);
            line-height: 1.6;
            margin-bottom: 16px;
        }

        .news-link {
            display: inline-flex;
            align-items: center;
            gap: 6px;
            color: var(--accent);
            text-decoration: none;
            font-size: 17px;
            font-weight: 500;
            transition: color 0.2s;
        }

        .news-link:hover {
            color: var(--accent-hover);
        }

        .news-link::after {
            content: "â†’";
            transition: transform 0.2s;
        }

        .news-link:hover::after {
            transform: translateX(4px);
        }

        /* Footer */
        footer {
            text-align: center;
            padding: 48px 0;
            color: var(--text-secondary);
            font-size: 14px;
            border-top: 1px solid var(--border);
            margin-top: 48px;
        }

        footer p {
            margin-bottom: 8px;
        }

        /* Language Flag */
        .lang-flag {
            font-size: 16px;
            margin-right: 8px;
        }

        /* Date Filter */
        .date-filter {
            display: flex;
            justify-content: center;
            gap: 8px;
            flex-wrap: wrap;
            margin-bottom: 32px;
        }

        .date-btn {
            padding: 8px 16px;
            border: 1px solid var(--border);
            border-radius: 20px;
            background: var(--bg-primary);
            color: var(--text-secondary);
            font-size: 14px;
            cursor: pointer;
            transition: all 0.2s ease;
            display: flex;
            flex-direction: column;
            align-items: center;
            min-width: 70px;
        }

        .date-btn:hover {
            border-color: var(--accent);
            color: var(--accent);
        }

        .date-btn.active {
            background: var(--accent);
            border-color: var(--accent);
            color: white;
        }

        .date-btn.weekend {
            background: var(--bg-secondary);
        }

        .date-btn.weekend.active {
            background: var(--accent);
        }

        .date-btn .weekday {
            font-size: 12px;
            opacity: 0.8;
        }

        .date-btn .date-display {
            font-weight: 500;
        }

        .filter-count {
            text-align: center;
            color: var(--text-secondary);
            font-size: 14px;
            margin-bottom: 24px;
        }

        .news-card.hidden {
            display: none;
        }

        /* Theme Switcher */
        .theme-switcher {
            position: fixed;
            top: 20px;
            right: 20px;
            display: flex;
            gap: 8px;
            background: var(--bg-secondary);
            padding: 8px;
            border-radius: 12px;
            box-shadow: 0 2px 10px rgba(0, 0, 0, 0.1);
            z-index: 1000;
        }

        .theme-btn {
            width: 32px;
            height: 32px;
            border: 2px solid transparent;
            border-radius: 8px;
            cursor: pointer;
            transition: all 0.2s ease;
            position: relative;
        }

        .theme-btn:hover {
            transform: scale(1.1);
        }

        .theme-btn.active {
            border-color: var(--accent);
        }

        .theme-btn[data-theme="minimal"] {
            background: linear-gradient(135deg, #ffffff 50%, #0071e3 50%);
        }

        .theme-btn[data-theme="pharma-blue"] {
            background: linear-gradient(135deg, #1a365d 50%, #2b6cb0 50%);
        }

        .theme-btn[data-theme="warm"] {
            background: linear-gradient(135deg, #faf8f5 50%, #d97706 50%);
        }

        /* Responsive */
        @media (max-width: 734px) {
            header {
                padding: 48px 0 40px;
            }

            h1 {
                font-size: 32px;
            }

            .subtitle {
                font-size: 17px;
            }

            .stats-bar {
                gap: 24px;
            }

            .stat-value {
                font-size: 24px;
            }

            .category-title {
                font-size: 24px;
            }

            .news-card {
                padding: 20px;
            }

            .news-card h3 {
                font-size: 19px;
            }
        }
    </style>
</head>
<body>
    <!-- Theme Switcher -->
    <div class="theme-switcher">
        <button class="theme-btn active" data-theme="minimal" title="ç®€çº¦ç™½"></button>
        <button class="theme-btn" data-theme="pharma-blue" title="åŒ»è¯è“"></button>
        <button class="theme-btn" data-theme="warm" title="æš–è‰²è°ƒ"></button>
    </div>

    <div class="container">
        <header>
            <div class="logo">ğŸ’Š</div>
            <h1>åˆ¶è¯æ—¥æŠ¥</h1>
            <p class="subtitle">Pharma Daily Â· 2026-01-22</p>
        </header>

        <div class="stats-bar">
            <div class="stat">
                <div class="stat-value">102</div>
                <div class="stat-label">æ–°é—»æ€»æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">4</div>
                <div class="stat-label">ç±»åˆ«æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">2026-01-22 03:46</div>
                <div class="stat-label">æ›´æ–°æ—¶é—´</div>
            </div>
        </div>

        <!-- Date Filter -->
        <div class="date-filter">
            <button class="date-btn active" data-filter="all">
                <span class="weekday">å…¨éƒ¨</span>
                <span class="date-display">All</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-16">
                <span class="weekday">å‘¨äº”</span>
                <span class="date-display">01/16</span>
            </button>
            
            <button class="date-btn weekend" data-filter="2026-01-17">
                <span class="weekday">å‘¨å…­</span>
                <span class="date-display">01/17</span>
            </button>
            
            <button class="date-btn weekend" data-filter="2026-01-18">
                <span class="weekday">å‘¨æ—¥</span>
                <span class="date-display">01/18</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-19">
                <span class="weekday">å‘¨ä¸€</span>
                <span class="date-display">01/19</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-20">
                <span class="weekday">å‘¨äºŒ</span>
                <span class="date-display">01/20</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-21">
                <span class="weekday">å‘¨ä¸‰</span>
                <span class="date-display">01/21</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-22">
                <span class="weekday">å‘¨å››</span>
                <span class="date-display">01/22</span>
            </button>
            
        </div>
        <div class="filter-count" id="filterCount"></div>

        
        <section class="analysis">
            <h2>ğŸ“Š ä»Šæ—¥æ¦‚è§ˆ</h2>
            <div class="analysis-content">
                <h3>ğŸ“Š AI æ™ºèƒ½åˆ†æ</h3>
<h4>ä»Šæ—¥æ¦‚è§ˆ</h4>
<p>ä»Šæ—¥åˆ¶è¯è¡Œä¸šåŠ¨æ€èšç„¦äºå¤§å‹è¯ä¼çš„æˆ˜ç•¥è°ƒæ•´ä¸é‡ç£…äº¤æ˜“ã€‚è¾‰ç‘ä»¥19äº¿ç¾å…ƒå‡ºå”®å…¶åœ¨GSKæ——ä¸‹ViiV Healthcareçš„è‚¡ä»½ï¼ŒGSKåˆ™ä»¥22äº¿ç¾å…ƒæ”¶è´­RAPT Therapeuticsä»¥æ‹“å±•é£Ÿç‰©è¿‡æ•è¯ç‰©ç®¡çº¿ã€‚å¼ºç”Ÿé¢„è®¡2026å¹´è¥æ”¶å°†çªç ´1000äº¿ç¾å…ƒï¼Œä¸»è¦å¾—ç›ŠäºDarzalexçš„å¼ºåŠ²å¢é•¿ã€‚</p>
<h4>ğŸ”¥ é‡ç‚¹æ–°é—»</h4>
<p><strong>1. Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€<br>
   - è¾‰ç‘å‡ºå”®å…¶æŒæœ‰çš„ViiVè‚¡ä»½ï¼Œæ¶‰åŠé‡‘é¢å·¨å¤§ï¼Œæ ‡å¿—ç€å…¶åœ¨HIVé¢†åŸŸæˆ˜ç•¥çš„é‡å¤§è°ƒæ•´ã€‚</p>
<p><strong>13. GSK to buy Rapt in $2.2B deal for food allergy drug</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€<br>
   - GSKä»¥22äº¿ç¾å…ƒæ”¶è´­RAPT Therapeuticsï¼Œæ˜¯å…¶æ–°ä»»CEOçš„é¦–ç¬”é‡å¤§äº¤æ˜“ï¼Œæ—¨åœ¨æ‹“å±•é£Ÿç‰©è¿‡æ•è¯ç‰©å¸‚åœºã€‚</p>
<p><strong>6. Led by Darzalex surge, J&J expects revenue to reach $100B in 2026</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: å¸‚åœºåˆ†æ<br>
   - å¼ºç”Ÿé¢„è®¡2026å¹´è¥æ”¶å°†çªç ´1000äº¿ç¾å…ƒï¼Œåæ˜ äº†å…¶æ ¸å¿ƒäº§å“Darzalexçš„å¼ºåŠ²å¸‚åœºè¡¨ç°å’Œå…¬å¸æ•´ä½“å¢é•¿é¢„æœŸã€‚</p>
<p><strong>4. IntraBio's Aqneursa, on a roll with EU approval, races toward another rare disease indication with phase 3 win</strong> â­â­â­â­<br>
   - ç±»åˆ«: ä¸´åºŠè¯•éªŒ<br>
   - IntraBioçš„è¯ç‰©åœ¨ç½•è§ç¥ç»é€€è¡Œæ€§ç–¾ç—…Ataxia-Telangiectasiaçš„IIIæœŸè¯•éªŒä¸­å–å¾—æˆåŠŸï¼Œå¹¶å·²è·å¾—æ¬§ç›Ÿæ‰¹å‡†ï¼Œæ˜¯ç½•è§ç—…é¢†åŸŸçš„é‡è¦è¿›å±•ã€‚</p>
<p><strong>8. Roche scales Genentechâ€™s North Carolina site to $2B in major obesity market play</strong> â­â­â­â­<br>
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€<br>
   - ç½—æ°å°†å¯¹å…¶Genentechåœ¨åŒ—å¡ç½—æ¥çº³å·çš„å·¥å‚æŠ•èµ„å¢è‡³çº¦20äº¿ç¾å…ƒï¼Œæ—¨åœ¨è¿›å†›å·¨å¤§çš„è‚¥èƒ–ç—‡å¸‚åœºï¼Œæ˜¯é‡å¤§äº§èƒ½å¸ƒå±€ã€‚</p>
<h4>ğŸ“ åˆ†ç±»æ‘˜è¦</h4>
<p><strong>æ–°è¯ç ”å‘</strong> (Drug R&D): ä»Šæ—¥æ–°è¯ç ”å‘åŠ¨æ€åŒ…æ‹¬IntraBioåœ¨ç½•è§ç—…è¯ç‰©ä¸Šçš„è¿›å±•ã€Corvusçš„æ¹¿ç–¹å£æœè¯æ—©æœŸç§¯ææ•°æ®ï¼Œä»¥åŠDefinium Therapeuticsæ¨è¿›è¿·å¹»è¯å€™é€‰è¯ç‰©çš„ç ”å‘ã€‚<br>
<strong>ä¸´åºŠè¯•éªŒ</strong> (Clinical Trials): ä¸´åºŠè¯•éªŒæ–¹é¢ï¼ŒIntraBioå®£å¸ƒå…¶æ²»ç–—Ataxia-Telangiectasiaçš„è¯ç‰©åœ¨å…³é”®IIIæœŸè¯•éªŒä¸­æˆåŠŸæ”¹å–„è¿åŠ¨åŠŸèƒ½ï¼Œæ˜¯ä»Šæ—¥æœ€çªå‡ºçš„ä¸´åºŠè¿›å±•ã€‚</p>
<h4>ğŸ”® æ˜æ—¥å…³æ³¨</h4>
<p>éœ€å…³æ³¨FDAå¯¹ValnevaåŸºå­”è‚¯é›…çƒ­ç–«è‹—Ixchiqå®‰å…¨è°ƒæŸ¥çš„è¿›å±•ã€GSKæ”¶è´­RAPT Therapeuticsäº¤æ˜“çš„åç»­ç»†èŠ‚ï¼Œä»¥åŠå¼ºç”ŸDarzalexç­‰æ ¸å¿ƒäº§å“çš„é”€å”®æ•°æ®å¯¹å¸‚åœºä¿¡å¿ƒçš„å½±å“ã€‚</p>
            </div>
        </section>
        

        <main>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç»¼åˆ</h2>
                    <span class="category-title-en"></span>
                    <span class="category-count">39 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Pfizer sells its stake in GSK&#39;s ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 09:29</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Five weeks after telling investors to expect a revenue decline in 2026, Pfizer has found a quick funding fix, selling off its stake in GSKâ€™s ViiV Healthcare. The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms of the agreement, Shionogi will pick up Pfizerâ€™s shares for $2.125 billion, with GSK gaining a special dividend of $250 million.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/pfizer-sells-its-stake-gsks-viiv-19b-shionogi-upping-its-ante-hiv-focused-company" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about antitrust claims by a compounder, FDA and EMA AI rules, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-15 14:12</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The FDA delayed reviews of two drugs chosen for the Trump administration&#39;s new fast-track program after agency scientists flagged safety and efficacy concerns</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/15/fda-antitrust-lilly-novo-compounders-insulin-ai-novartis/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        IntraBio&#39;s Aqneursa, on a roll with EU approval, races toward another rare disease indication with phase 3 win
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-21 11:04</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The company announced a phase 3 win in the rare neurodegenerative disease Ataxia-Telangiectasia on the same day it snagged a key European approval in the drug&#39;s original indication of Niemann-Pick disease type C.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/intrabios-aqneursa-roll-eu-approval-races-toward-another-rare-disease-indication-phase-3-win" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Led by Darzalex surge, J&amp;amp;J expects revenue to reach $100B in 2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-21 11:20</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Led by cancer standout Darzalex, Johnson &amp;amp; Johnson projects that its 2026 revenue will reach between $100 billion and $101 billion. With J&amp;amp;J also forecasting double-digit revenue increases by the end of the decade, the drugmaker may be on its way to kicking off a $100-billion-plus annual revenue streak.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/led-darzalex-surge-jj-expects-revenue-reach-100b-2026" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Definium defines mental health applications for LSD in new awareness campaign
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 11:30</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">As it inches closer to FDA submissions for its psychedelic drug candidate, Definium Therapeutics is laying the groundwork for a future launch with an educational push about the pharmaceutical potential of LSD.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/definium-defines-mental-health-applications-lsd-new-awareness-campaign" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Roche scales Genentechâ€™s North Carolina site to $2B in major obesity market play
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 11:47</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Roche is more than doubling its total commitment to a future facility for its Genentech unit to approximately $2 billion. The plant, being built in Holly Springs, North Carolina, will be used to crank out next-generation drugs for metabolic conditions like obesity, Roche has said.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/roche-beefs-investment-genentechs-future-nc-obesity-drug-factory-2b" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Valneva withdraws chikungunya vaccine Ixchiq from US amid new FDA investigation
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 09:53</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Following an FDA marketing suspension, Valneva has decided to voluntarily withdraw its chikungunya vaccine Ixchiq in the U.S. The FDA has also opened an investigation into a newly reported serious adverse event.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/valneva-withdraws-chikungunya-vaccine-ixchiq-us-amid-new-fda-investigation" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drug approvals went from crawl to sprint in 2025
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-15 16:37</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">On this episode of &#34;The Top Line,&#34; we dig into how turmoil at the FDA impacted drug approvals in 2025.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/drug-approvals-went-crawl-sprint-2025" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about Canada speeding drug reviews, Novo Nordisk ads, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-21 14:14</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Health Canada is planning to speed up reviews of some drugs by piggybacking on the decisions of foreign regulators, including possibly the U.S. FDA</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/21/canada-vaccines-novo-eczema-diabetes/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: GSK to buy RAPT Therapeutics, maker of food allergy treatment, in $2.2B deal
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-20 08:01</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">GSK is buying RAPT Therapeutics in a deal worth $2.2 billion, picking up an experimental medicine for food allergies.</p>
                    
                    <a href="https://www.statnews.com/2026/01/20/gsk-rapt-therapeutics-acquisition-food-allergy-prophylaxis-ozureprubart/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: FDA delays reviews for two drugs in new voucher program
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-16 14:36</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">And more biotech news, brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/01/16/biotech-news-fda-delays-review-in-voucher-program/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about FDA voucher worries, weight loss drugs and jet fuel, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-16 14:30</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Some major drugmakers are hesitating to participate in the Trump administration&#39;s speedier review program for new medicines over possible legal risks</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/16/trump-fda-voucher-obesity-novo-lilly-covid/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Single-drug Exelixis aims to be top 5 solid tumor company in the US: CEO
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-16 10:16</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Exelixis may only have one drug on the market right now, but with phase 3 results for a potential new blockbuster on the horizon and a growing pipeline, the Cabometyx maker is aiming big.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/single-product-exelixis-aims-be-top-5-solid-tumor-drugmaker-us" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        In J&amp;amp;J talc litigation, N.J. court-appointed official recommends allowing expert testimony
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-21 15:13</span>
                        
                    </div>
                    
                    <p class="news-summary">In Johnson &amp;amp; Johnson&#39;s long-running talc litigation, a court-appointed special master has recommended that plaintiffs should be able to present testimony from expert witnesses who can speak to scientific evidence backing their claims. The decision could negatively impact the company&#39;s defense of lawsuits from those who claim Johnsonâ€™s Baby Powder caused their cancer.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/jj-talc-litigation-nj-court-recommends-allow-expert-testimony" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        UPDATE: In quick reversal, Trump calls off tariff threat related to Greenland pursuit
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 09:55</span>
                        
                    </div>
                    
                    <p class="news-summary">Only a few days after threatening to impose new tariffs on a group of European countries related to his pursuit of Greenland, the president has called off the threat.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/trumps-new-tariff-threats-around-greenland-threaten-upend-eu-trade-deal" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Pfizer CEO lays blame for US vaccine woes on RFK Jr.&#39;s &#39;anti-science&#39; stance: WSJ
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-21 09:46</span>
                        
                    </div>
                    
                    <p class="news-summary">While much of the biopharma industry has spent the past 12 months treading lightly around the Trump administration and the tumult it has wrought on U.S. medical research and regulation, Pfizerâ€™s CEO cut to the chase this week in a blatant rebuke of HHS Secretary Robert F. Kennedy Jr., according to The Wall Street Journal.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/pfizer-ceo-lays-blame-us-vaccine-woes-anti-science-rfk-jr-wsj" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Rising Stars: Regeneronâ€™s Catie Matthews on updating marketing strategy to meet the AI boom
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 12:30</span>
                        
                    </div>
                    
                    <p class="news-summary">In a Q&amp;amp;A for Fierce Pharma Marketingâ€™s â€œRising Starsâ€ series, Catie Matthews suggested that marketers should embrace artificial intelligence in their own lives.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/rising-stars-regenerons-catie-matthews-updating-marketing-strategy-amid-ai-boom" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        GSK licenses Alteogen enzyme in bid to develop subQ Jemperli
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 14:08</span>
                        
                    </div>
                    
                    <p class="news-summary">GSK, through its oncology subsidiary Tesaro, is handing over $20 million upfront to Alteogen for global rights to the Korean biotechâ€™s novel hyaluronidase ALT-B4. Tesaro plans to use ALT-B4 to develop and potentially market a subcutaneous form of the ascendant cancer med Jemperli.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/gsk-offers-alteogen-285m-subq-jemperli-licensing-pact" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Takeda&#39;s neuroscience field force hit with layoffs as key patent loss looms for Trintellix
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 13:14</span>
                        
                    </div>
                    
                    <p class="news-summary">Takeda is executing another round of layoffs, cutting 243 roles in the United States. The company is preparing for an upcoming patent loss on depression drug Trintellix.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/takeda-cuts-243-us-workers-generic-competition-looms-trintellix" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Supreme Court agrees to review &#39;skinny label&#39; battle between Hikma, Amarin over generic Vascepa
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 11:27</span>
                        
                    </div>
                    
                    <p class="news-summary">The U.S. Supreme Court will hear a case involving the &#34;skinny label&#34; practice of generic drugmakers, with its review particularly relating to Hikma&#39;s marketing of its generic version of Amarin&#39;s Vascepa.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/supreme-court-agrees-review-skinny-label-battle-hikma-amarin-over-generic-vascepa" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Curia&#39;s Mass. plant closure to eliminate 81 jobs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 17:08</span>
                        
                    </div>
                    
                    <p class="news-summary">Curia Global is laying off 81 employees as part of its plan to shut down its drug product development and manufacturing facility in Burlington, Massachusetts, according to a Worker Adjustment and Retraining Notification.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/curia-plant-shutdown-massachusetts-forces-lay-81" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Apiject signs lease for new generics blow-fill-seal manufacturing facility in N.C.
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 08:33</span>
                        
                    </div>
                    
                    <p class="news-summary">Prefilled drug delivery device specialist Apiject has signed a lease for a new site in Apex, North Carolina, that will house two blow-fill-seal production lines.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/apiject-signs-lease-new-generics-blow-fill-seal-facility-north-carolina" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo riffs on Appleâ€™s â€˜Get a Macâ€™ ads in Ozempic push starring Justin Long, John Hodgman
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-16 15:28</span>
                        
                    </div>
                    
                    <p class="news-summary">Amid a viral social media trend glorifying the halcyon days of 2016, Novo Nordisk has gone back an extra decade to find inspiration for its latest direct-to-consumer Ozempic campaign.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/novo-riffs-apples-get-mac-ads-ozempic-push-starring-justin-long-john-hodgman" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        From approval to value: Why evidence storytelling now matters
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-15 15:46</span>
                        
                    </div>
                    
                    <p class="news-summary">RTI Health Solutions experts explain how HEOR and real-world evidence are reshaping access decisionsâ€”and why clear communication is essential.</p>
                    
                    <a href="https://www.fiercepharma.com/sponsored/approval-value-why-evidence-storytelling-now-matters" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        After AbbVie and Genmab&#39;s ph. 3 survival miss for Epkinly in DLBCL, what&#39;s next?
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-16 15:29</span>
                        
                    </div>
                    
                    <p class="news-summary">Just days after AbbVie unveiled a major new oncology play in the form of its high-dollar RemeGen collab, the Illinois drugmaker closed out the week with some mixed news for marketed cancer offering Epkinly.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/after-abbvie-and-genmabs-ph-3-survival-miss-epkinly-dlbcl-whats-next" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        JPM26: Fujifilm CEO touts biologics capacity edge amid expansion tear
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-16 10:52</span>
                        
                    </div>
                    
                    <p class="news-summary">With Fujifilm Biotechnologies now among the top echelon of CDMOs by biologics capacity, Fujifilmâ€™s group CEO reflected on the unitâ€™s unique facility design philosophy and how itâ€™s eschewing big M&amp;amp;A plays to expand in-house.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/jpm26-fujifilm-ceo-touts-biologics-capacity-edge-manufacturing-unit-keeps-expansions-coming" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AbbVieâ€™s Skyrizi takes full-year TV ad spending crown yet again, with J&amp;amp;Jâ€™s Tremfya in hot pursuit
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-16 10:49</span>
                        
                    </div>
                    
                    <p class="news-summary">For the fourth year runningâ€”and the third in a row for Skyrizi specificallyâ€”an AbbVie immunology med has claimed the top spot in the full-year TV drug ad spending rankings.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/abbvies-skyrizi-takes-full-year-tv-ad-spending-crown-yet-again-jjs-tremfya-hot-pursuit" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Fierce Pharma Asiaâ€”AbbVieâ€™s bispecific play, Illuminaâ€™s China import efforts and pharma execsâ€™ JPM comments
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-15 10:47</span>
                        
                    </div>
                    
                    <p class="news-summary">In this week&#39;s Asia news recap, AbbVie struck a big deal to enter the hot PD-1xVEGF bispecific space, while Illumina&#39;s CEO detailed the company&#39;s efforts to work with authorities in China. In addition, Astellas CEO Naoki Okamura updated the audience at Fierce JPM Week on the company&#39;s approach to dealmaking.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/fierce-pharma-asia-abbvies-bispecific-play-illuminas-china-import-efforts-and-pharma-execs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Former Emergent CEO Kramer faces insider trading allegations in NY
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-15 16:21</span>
                        
                    </div>
                    
                    <p class="news-summary">New York&#39;s attorney general has filed an insider trading lawsuit against former Emergent BioSolutions CEO Robert Kramer, accusing him of selling company shares and receiving more than $10 million before the company revealed contamination issues at a plant in Baltimore. As part of the action, New York also announced a $900,000 million settlement with the company.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/former-emergent-ceo-kramer-faces-insider-trading-allegations-ny" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Novo strikes deal for diabetes cell therapies
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-21 14:53</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news, brought to you by The Readout newsletter</p>
                    
                    <a href="https://www.statnews.com/2026/01/21/biotech-news-novo-nordisk-acquires-aspect-biosystems/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Congress revives health care deal with PBM reforms
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-20 15:31</span>
                        
                    </div>
                    
                    <p class="news-summary">This is the web edition of D.C. Diagnosis, STAT&#39;s twice-weekly newsletter about the politics and policy of health and medicine.</p>
                    
                    <a href="https://www.statnews.com/2026/01/20/congress-revives-health-care-deal-pbm-reforms-dc-diagnosis-newsletter/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Benefit from Modernaâ€™s skin cancer immunotherapy endures
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-20 14:47</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news brought to you by the Readout Newsletter</p>
                    
                    <a href="https://www.statnews.com/2026/01/20/biotech-news-moderna-merck-skin-cancer-mrna/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about drug prices in Europe, a cancer vaccine, and much more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-20 14:20</span>
                        
                    </div>
                    
                    <p class="news-summary">U.S. pharmaceutical companies are stepping up their campaign for higher drug prices in Europe, in some cases threatening to withhold new medicines</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/20/pharma-prices-china-gsk-aids-cancer-vaccine-europe/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Florida proposes cutting eligibility for an AIDS drug program, causing panic
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-20 09:30</span>
                        
                    </div>
                    
                    <p class="news-summary">In a surprise move, Florida officials have proposed drastically reducing eligibility for the state AIDS drug assistance program.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/20/florida-hiv-aids-gilead-health-insurance/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Congress revives bipartisan health care proposal, including drug middlemen provisions
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-20 01:03</span>
                        
                    </div>
                    
                    <p class="news-summary">Elements of a health care deal that was blown up by Elon Musk are getting a fresh look in Congress.</p>
                    
                    <a href="https://www.statnews.com/2026/01/19/bipartisan-health-care-package-pharmacy-benefit-manager/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Supreme Court agrees to review â€˜skinny labelingâ€™ and generic drug access
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-16 21:03</span>
                        
                    </div>
                    
                    <p class="news-summary">The Supreme Court agreed to review a controversy over so-called skinny labels for medicines, a decision that will be closely watched for its implications for the availability of generic medicines.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/16/scotus-generics-patents-supreme-court-amarin-hikma/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Up and down the ladder: The latest comings and goings
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-16 17:00</span>
                        
                    </div>
                    
                    <p class="news-summary">From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/16/pharma-biotech-jobs-novo-bristol-astrazeneca/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Trump releases health care plan amid pressure over affordability
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-15 18:10</span>
                        
                    </div>
                    
                    <p class="news-summary">Trump&#39;s most consequential proposals would require action from Congress.</p>
                    
                    <a href="https://www.statnews.com/2026/01/15/trump-great-healthcare-plan-potential-stumbling-blocks/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Former Emergent BioSolutions CEO sued for insider trading, company reaches $900K settlement in N.Y.
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-15 17:55</span>
                        
                    </div>
                    
                    <p class="news-summary">The former CEO of Emergent BioSolutions was accused of insider trading by the New York attorney general in connection with a Covid-era contract.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/15/covid-insider-trading-stock-emergent-astrazeneca/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">æ–°è¯ç ”å‘</h2>
                    <span class="category-title-en">Drug R&amp;D</span>
                    <span class="category-count">34 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        J&amp;J praises new FDA guidance to speed development of multiple myeloma drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 18:35</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Johnson &amp;amp; Johnson, which has several drugs approved for multiple myeloma, praised the FDA&#39;s just-released draft guidance on how the agency will allow the use of minimal residual disease as a primary endpoint for accelerated ...</p>
                    
                    <a href="https://endpoints.news/jj-praises-new-fda-guidance-to-speed-development-of-multiple-myeloma-drugs/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        IntraBio says rare disease drug passes Phase 3, will seek FDA approval
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 16:05</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">IntraBio said Wednesday that its treatment improved motor function for a rare genetic disorder called ataxia-telangiectasia as part of a pivotal study. The Austin, TX-based biotech told Endpoints News it plans to submit an application ...</p>
                    
                    <a href="https://endpoints.news/intrabio-says-rare-disease-drug-passes-phase-3-will-seek-fda-approval/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Corvus shares nearly triple on positive data for eczema pill
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-21 16:39</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed with the injectable biologic Dupixent.</p>
                    
                    <a href="https://www.biopharmadive.com/news/corvus-soquelitinib-phase-1-data-eczema-pill/810080/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Valneva to withdraw Chikungunya vaccine from US amid safety woes
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-20 16:47</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The decision comes months after the FDA had suspended the vaccine&amp;rsquo;s license. One analyst speculated the company might shelve the product altogether.&amp;nbsp;</p>
                    
                    <a href="https://www.biopharmadive.com/news/valneva-fda-withdrawl-application-chikungunya-Ixchiq-vaccine/809994/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        GSK to buy Rapt in $2.2B deal for food allergy drug
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-20 15:57</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines businesses.</p>
                    
                    <a href="https://www.biopharmadive.com/news/gsk-rapt-acquire-food-allergy-prophylaxis-drug-ozureprubart/809956/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Kaileraâ€™s Ron Renaud on how a China-linked startup can compete in obesity
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-20 12:00</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">In an interview with BioPharma Dive, the veteran biotech CEO said there remains a &amp;ldquo;significant opportunity&amp;rdquo; for young companies in a market dominated by Novo Nordisk and Eli Lilly.</p>
                    
                    <a href="https://www.biopharmadive.com/news/kailera-ron-renaud-obesity-hengrui-rebupatide/809798/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        When every day counts: Building CRO partnerships on a foundation of trust, care and precision
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-20 10:00</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Clinical trial delays impact outcomes. Learn why CROs need a supply chain partner they can trust to reduce delays and help patients.&amp;nbsp;</p>
                    
                    <a href="https://www.biopharmadive.com/spons/when-every-day-counts-building-cro-partnerships-on-a-foundation-of-trust/809569/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-16 16:24</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">More than 3,000 prescriptions were written for Novo&amp;rsquo;s GLP-1 pill in its first week on the market. Elsewhere, Emergent reached a settlement over a trading scandal and Sanofi is reportedly circling an eye drug biotech.</p>
                    
                    <a href="https://www.biopharmadive.com/news/wegovy-pill-sales-emergent-sanofi-ocular-jazz-novo/809709/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Government funding bill features PBM reforms, voucher reauthorization
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-20 19:14</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The House is set to vote this week on a bipartisan bill to keep the government open beyond Jan. 30, with new proposals to change how pharmacy benefit managers operate and to reauthorize a lapsed ...</p>
                    
                    <a href="https://endpoints.news/government-funding-bill-features-pbm-reforms-voucher-reauthorization/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Pfizer to depart GSK&#39;s ViiV as Shionogi doubles its stake
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-20 12:02</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Pfizer is walking away from a specialist HIV company it created together with GSK more than a decade ago, with Shionogi taking its place. The Japanese drugmaker will buy about $2.13 billion worth of new ...</p>
                    
                    <a href="https://endpoints.news/pfizer-to-depart-gsks-viiv-as-shionogi-doubles-its-stake/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        GSK makes $2.2B deal for RAPT and its food allergy candidate
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-20 10:34</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The biopharma industry was hungry for an M&amp;amp;A deal during last weekâ€™s JP Morgan Healthcare Conference. It&#39;s finally getting one. GSK is scooping up RAPT Therapeutics for $2.2 billion, with a $1.9 billion upfront investment ...</p>
                    
                    <a href="https://endpoints.news/gsk-makes-2-2b-deal-for-rapt-and-its-food-allergy-candidate/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Agomab and SpyGlass file for IPOs as investor enthusiasm builds after JPM
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-16 22:05</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">SpyGlass Pharma and Agomab Therapeutics filed for initial public offerings on Friday evening. The drug developers hope to build on the strong start set by Aktis Oncologyâ€™s $318 million Nasdaq listing last ...</p>
                    
                    <a href="https://endpoints.news/agomab-and-spyglass-file-for-ipos-as-investor-enthusiasm-builds-after-jpm/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Fosun-funded Hygtia Therapeutics licenses Insilicoâ€™s NLRP3 inhibitor for Parkinsonâ€™s
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 12:14</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">A biotech funded by Shanghai Fosun Pharmaceutical is licensing a preclinical asset developed by Insilico Medicine in the NLRP3 space, which has garnered industry interest in recent months. Hygtia Therapeutics will get half the global ...</p>
                    
                    <a href="https://endpoints.news/fosun-funded-hygtia-therapeutics-licenses-insilicos-nlrp3-inhibitor-for-parkinsons/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Corvus&#39; new Phase 1 atopic dermatitis data meet high expectations
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-20 12:00</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Corvus Pharmaceuticalsâ€™ therapy for severe atopic dermatitis is heading to mid-stage trials this quarter following an update from an ongoing Phase 1 study that met analysts&#39; best-case scenario. The company&#39;s share price {$CRVS} soared more ...</p>
                    
                    <a href="https://endpoints.news/corvus-new-phase-1-atopic-dermatitis-data-meet-high-expectations/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Exciva raises $59M Series B to fund Phase 2 test of Alzheimerâ€™s agitation drug
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-20 06:30</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Exciva has secured â‚¬51 million ($59 million) in a Series B raise to advance its candidate for a common behavioral symptom of Alzheimerâ€™s disease into mid-stage development. The German biotech will use the proceeds to ...</p>
                    
                    <a href="https://endpoints.news/exciva-raises-59m-series-b-to-fund-phase-2-test-of-alzheimers-agitation-drug/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AbbVie, Genmab say Epkinly didn&#39;t prolong overall survival in lymphoma study
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-16 21:01</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">AbbVie and Genmabâ€™s cancer drug Epkinly failed to improve overall survival in a late-stage study for diffuse large B cell lymphoma. The Phase 3 trial enrolled patients who had received at least one prior therapy ...</p>
                    
                    <a href="https://endpoints.news/abbvie-genmab-say-epkinly-didnt-prolong-overall-survival-in-lymphoma-study/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        J&amp;J eyes $100B in sales amid gains for cancer, immune drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-21 16:04</span>
                        
                    </div>
                    
                    <p class="news-summary">Amid patent expirations, litigation and tariff costs, J&amp;amp;J says it expects more growth ahead, fueled in part by its blood cancer medicines and a closely watched psoriasis pill.</p>
                    
                    <a href="https://www.biopharmadive.com/news/johnson-johnson-2025-earnings-sales-cancer-immune-drugs/810097/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Moderna cancer vaccine holds up; IO Biotech considers a sale
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-21 15:38</span>
                        
                    </div>
                    
                    <p class="news-summary">Long-term data suggest Moderna&amp;rsquo;s personalized melanoma shot provides &amp;ldquo;durable tumor control,&amp;rdquo; one analyst said. Elsewhere, Insilico Medicine partnered with a startup on a popular drug target.</p>
                    
                    <a href="https://www.biopharmadive.com/news/moderna-melanoma-io-biotech-nlrp3-think-pfizer-novavax/809958/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        The patient retention crisis is happening before enrollment even begins
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-20 10:00</span>
                        
                    </div>
                    
                    <p class="news-summary">The biggest patient drop-off happens before patients ever enroll.</p>
                    
                    <a href="https://www.biopharmadive.com/spons/the-patient-retention-crisis-is-happening-before-enrollment-even-begins/809568/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        On biotechâ€™s biggest stage, renewed excitement gets a stress test
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-16 11:43</span>
                        
                    </div>
                    
                    <p class="news-summary">A surge in deals and financings had the industry abuzz heading into this year&amp;rsquo;s J.P. Morgan Healthcare Conference. But some aren&amp;rsquo;t sure if the rebound is here to stay.</p>
                    
                    <a href="https://www.biopharmadive.com/news/jpm26-biotech-startups-deals-venture-ipo-fda-china/809809/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        The status of EU drug price talks depends on who you ask
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 20:33</span>
                        
                    </div>
                    
                    <p class="news-summary">One of the main questions for drugmakers entering 2026, and one they hope tilts in their favor, is whether the US will successfully pressure Europe to raise the price it pays for drugs. Three weeks ...</p>
                    
                    <a href="https://endpoints.news/the-status-of-eu-drug-price-talks-depends-on-who-you-ask/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Johnson &amp; Johnson brushes off MFN impact, sees strong growth for 2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 16:43</span>
                        
                    </div>
                    
                    <p class="news-summary">As the calendar turns from JPM to quarterly reports, earnings bellwether Johnson &amp;amp; Johnson makes its return for 2026. The focus this time? How biopharma will react to a slate of most favored nation deals ...</p>
                    
                    <a href="https://endpoints.news/johnson-johnson-brushes-off-mfn-impact-sees-strong-growth-for-2026/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Tanabe pill delays blood disorder; enGene adds up to $100M from loans
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 16:25</span>
                        
                    </div>
                    
                    <p class="news-summary">Plus, news about IO, ErVimmune, Affibody, Clasp Therapeutics and Infinitopes: ğŸ’Š Tanabe Pharmaâ€™s pill succeeds in rare blood conditions: The biotechâ€™s oral melanocortin-1 receptor delayed the onset of symptoms in a ...</p>
                    
                    <a href="https://endpoints.news/tanabe-pill-delays-blood-disorder-engene-adds-up-to-100m-from-loans/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        #JPM26: Regeneron, Lilly, Summit on rivals crowding into same targets
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 14:00</span>
                        
                    </div>
                    
                    <p class="news-summary">There are countless diseases lacking a single good treatment, but drugmakers are still herding into the same targets, particularly in chasing after megablockbusters. George Yancopoulos, the outspoken co-founder and chief scientific officer of Regeneron, is ...</p>
                    
                    <a href="https://endpoints.news/jpm26-regeneron-lilly-summit-on-rivals-crowding-into-same-targets/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Exclusive: Claim Health raises $4.4M to help home care providers get paid
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 14:00</span>
                        
                    </div>
                    
                    <p class="news-summary">After an initial wave of AI startups that automated specific administrative tasks in healthcare, companies are now racing to handle the entire process. Claim Health, which aims to manage every step of how home care ...</p>
                    
                    <a href="https://endpoints.news/exclusive-claim-health-raises-4-4m-to-help-home-care-providers-get-paid/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Think Bioscience gets $55M to unearth new drug pockets
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 12:00</span>
                        
                    </div>
                    
                    <p class="news-summary">A Boulder, CO-based startup is searching for previously undiscovered footholds â€” not on rocks, but on molecules. Think Bioscience has raised a $55 million Series A led by investors including Regeneron Ventures ...</p>
                    
                    <a href="https://endpoints.news/think-bioscience-gets-55m-to-unearth-new-drug-pockets/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        EU Parliament adopts stricter drug stockpiling rules under Critical Medicines Act
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-20 18:55</span>
                        
                    </div>
                    
                    <p class="news-summary">The European Parliament has adopted proposals aimed at reducing critical drug shortages across the EU, including stricter stockpiling rules and incentives for companies to boost manufacturing capacity. On Tuesday, the European Parliament adopted the Critical ...</p>
                    
                    <a href="https://endpoints.news/eu-parliament-adopts-stricter-drug-stockpiling-rules-under-critical-medicines-act/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Valneva withdraws chikungunya vaccine from US
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-20 18:37</span>
                        
                    </div>
                    
                    <p class="news-summary">Valneva has taken its chikungunya vaccine out of the US market, withdrawing its suspended product and a now-halted post-marketing study. The company said Monday that it decided to voluntarily withdraw its ...</p>
                    
                    <a href="https://endpoints.news/valneva-withdraws-chikungunya-vaccine-from-us/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Clinician groups ask court to overturn CDC&#39;s childhood vaccine overhaul
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-20 15:54</span>
                        
                    </div>
                    
                    <p class="news-summary">Leading clinician groups are asking a federal court to undo the US overhaul of the childhood vaccine schedule, calling the move the â€œmost egregious, reckless, and dangerousâ€ action that HHS Secretary Robert F. Kennedy Jr ...</p>
                    
                    <a href="https://endpoints.news/clinician-groups-ask-court-to-overturn-cdcs-childhood-vaccine-overhaul/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Aspect Bio takes Novo castoff therapies; Takeda trims US jobs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-20 14:58</span>
                        
                    </div>
                    
                    <p class="news-summary">Plus, news about AstraZeneca, AbelZeta, Novavax, Pfizer, Alteogen, Tesaro, Epidarex Capital and Boundless Bio: ğŸ¤ Aspect Biosystems picks up Novo Nordiskâ€™s castoff cell therapies: The Vancouver biotech has taken over stem cell-derived islet cell and ...</p>
                    
                    <a href="https://endpoints.news/aspect-bio-takes-novo-castoff-therapies-takeda-trims-us-jobs/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Teladocâ€™s mental health arm BetterHelp has quietly expanded the use of AI
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-20 13:00</span>
                        
                    </div>
                    
                    <p class="news-summary">One of the largest virtual mental health companies has been warming up to using AI. Teladocâ€™s BetterHelp, which calls itself the worldâ€™s largest therapy service with over 32,000 therapists, now uses AI to recommend goals ...</p>
                    
                    <a href="https://endpoints.news/teladocs-mental-health-arm-betterhelp-has-quietly-expanded-the-use-of-ai/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        2025 ended on high note with a buoyant Q4 for M&amp;A, PIPEs and follow-ons
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-20 13:00</span>
                        
                    </div>
                    
                    <p class="news-summary">After a downbeat start to 2025, biopharma struck some high notes in the second half and ended the year with strong Q4 momentum in dealmaking, fundraising and M&amp;amp;A. The numbers, once again tracked for us ...</p>
                    
                    <a href="https://endpoints.news/2025-ended-on-high-note-with-a-buoyant-q4-for-ma-pipes-and-follow-ons/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        J&amp;J, Isomorphic sign research deal for AI-made molecules
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-20 12:00</span>
                        
                    </div>
                    
                    <p class="news-summary">The Google DeepMind spinout Isomorphic Labs has landed its third pharma deal. The AI-focused biotech has signed a multi-target research deal with Johnson &amp;amp; Johnson, the two companies announced Tuesday. Isomorphic, founded in 2021 and ...</p>
                    
                    <a href="https://endpoints.news/jj-isomorphic-sign-research-deal-for-ai-made-molecules/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-17">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        JPM recap; Mirador raises $250M; Genentechâ€™s PBM shift; and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-17 11:00</span>
                        
                    </div>
                    
                    <p class="news-summary">Welcome back to Endpoints Weekly! One programming note before we dive into news from #JPM26: We wonâ€™t be sending newsletters on Monday, but weâ€™ll be back in your inbox on Tuesday. The Endpoints News ...</p>
                    
                    <a href="https://endpoints.news/jpm-recap-mirador-raises-250m-genentechs-pbm-shift-and-more/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç›‘ç®¡å®¡æ‰¹</h2>
                    <span class="category-title-en">Regulatory</span>
                    <span class="category-count">20 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        What&#39;s New Related to Drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 22:55</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Want to know what&#39;s new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.</p>
                    
                    <a href="http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drug Trials Snapshots
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 22:45</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Drug Trials Snapshots: breaking down the what, how and why. Drug Trials Snapshots is part of an overall FDA effort to make demographic data more available and transparent.</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Importing Liquid Cough and Cold Medicine from India
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 17:56</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA is aware of news reports of devastating, ongoing diethylene glycol (DEG) and ethylene glycol (EG) contamination in childrenâ€™s cough and cold medicine in India.</p>
                    
                    <a href="http://www.fda.gov/drugs/human-drug-imports/importing-liquid-cough-and-cold-medicine-india" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drug Alerts and Statements
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 15:01</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA Drug Alerts and Statements</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-safety-and-availability/drug-alerts-and-statements" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA Announces PreCheck Implementation Roadmap
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 15:00</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The U.S. Food and Drug Administration announced that it will begin accepting applications on Feb. 1, 2026 for the PreCheck Pilot Program, a program to strengthen the domestic pharmaceutical supply chain. Learn more.</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-precheck-implementation-roadmap" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drugs@FDA Data Files
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 14:19</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        GDUFA IV: Fiscal Years 2028 â€“ 2032
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-20 21:42</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Information related to FDAâ€™s preparation for the fourth reauthorization of GDUFA will be hosted on this page as it becomes available.</p>
                    
                    <a href="http://www.fda.gov/industry/generic-drug-user-fee-amendments/gdufa-iv-fiscal-years-2028-2032" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        For Healthcare Professionals | FDAâ€™s Examples of Drugs that Interact with CYP Enzymes and Transporter Systems
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-20 19:55</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDAâ€™s Examples of Interacting Drugs and Other Substances Involving CYP Metabolic- and Transporter System-Based Pathways for Healthcare Professionals</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Antimicrobial Resistance
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-20 17:18</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Antimicrobial resistance (AMR)â€”the ability of a microorganism (bacteria, virus, fungi, parasite) to resist the effects of a drugâ€”is a serious, complex and costly public health problem. Learn what FDA is doing to address AMR.</p>
                    
                    <a href="http://www.fda.gov/emergency-preparedness-and-response/mcm-issues/antimicrobial-resistance" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novel Drug Approvals for 2025
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 22:45</span>
                        
                    </div>
                    
                    <p class="news-summary">Innovative drugs often mean new treatment options for patients and advances in health care for the American public.</p>
                    
                    <a href="http://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drug Trials Snapshots KYGEVVI
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 22:43</span>
                        
                    </div>
                    
                    <p class="news-summary">Drug Trials Snapshots KYGEVVI</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-kygevvi" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Compounding Quality Center of Excellence | Instructor-Led Trainings
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 21:32</span>
                        
                    </div>
                    
                    <p class="news-summary">The Compounding Quality Center of Excellenceâ€™s free in-person training programs target outsourcing facility staff and offer continuing education credits. The training will open for state regulators and pharmacy compounders if space is available.</p>
                    
                    <a href="http://www.fda.gov/drugs/compounding-quality-center-excellence/compounding-quality-center-excellence-instructor-led-trainings" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drug Facilities, Sites and Organization Lists
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 19:53</span>
                        
                    </div>
                    
                    <p class="news-summary">Generic Drug Facilities, Sites and Organization Lists</p>
                    
                    <a href="http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Quality and Regulatory Predictability: Shaping USP Standards - 12/11/2025
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 16:26</span>
                        
                    </div>
                    
                    <p class="news-summary">This discussion will show how USP public standards strengthen quality, streamline development, support regulatory compliance, and overall, increase regulatory predictability for drugs.</p>
                    
                    <a href="http://www.fda.gov/drugs/news-events-human-drugs/quality-and-regulatory-predictability-shaping-usp-standards-12112025" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Recently Issued Guidance Documents
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 14:35</span>
                        
                    </div>
                    
                    <p class="news-summary">This page lists Recently Issued CBER and Cross-Center Guidance Documents.</p>
                    
                    <a href="http://www.fda.gov/vaccines-blood-biologics/biologics-guidances/recently-issued-guidance-documents" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Information for Health Care Professionals | Drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 14:19</span>
                        
                    </div>
                    
                    <p class="news-summary">Drug Information for Health Care Professionals, including drug labeling and safety information.</p>
                    
                    <a href="http://www.fda.gov/drugs/resources-drugs/information-health-care-professionals-drugs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        M4Q(R2) The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 12:45</span>
                        
                    </div>
                    
                    <p class="news-summary">M4Q(R2) The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality</p>
                    
                    <a href="http://www.fda.gov/regulatory-information/search-fda-guidance-documents/m4qr2-common-technical-document-registration-pharmaceuticals-human-use-quality" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        CDER Small Business and Industry Assistance (SBIA) Learn
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-20 21:38</span>
                        
                    </div>
                    
                    <p class="news-summary">SBIA Learn offers a variety of multimedia resources to provide information that is comprehensive, interactive, and easily accessible to small pharmaceutical business and industry.</p>
                    
                    <a href="http://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/cder-small-business-and-industry-assistance-sbia-learn" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Office of Study Integrity and Surveillance (OSIS) Workshop 2022: CDER Inspections of Good Laboratory Practice, Animal Rule, and Bioavailability/Bioequivalence Study Sites - 07/19/2022
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-20 21:32</span>
                        
                    </div>
                    
                    <p class="news-summary">Office of Study Integrity and Surveillance (OSIS) Workshop 2022&amp;amp;#58; CDERInspections of Good Laboratory Practice, Animal Rule, and Bioavailability/Bioequivalence Study Sites</p>
                    
                    <a href="http://www.fda.gov/drugs/news-events-human-drugs/office-study-integrity-and-surveillance-osis-workshop-2022-cder-inspections-good-laboratory-practice" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        The ABCs of Product-Specific Guidances | Audio Transcript
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-20 17:44</span>
                        
                    </div>
                    
                    <p class="news-summary">PSGs help streamline generic drug product development, promoting timely approval of abbreviated new drug application, or ANDA, submissions and increasing drug competition, ultimately improving patient access to high quality and affordable medicines.</p>
                    
                    <a href="http://www.fda.gov/drugs/development-approval-process-drugs/abcs-product-specific-guidances-audio-transcript" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">å•†ä¸šåŠ¨æ€</h2>
                    <span class="category-title-en">Business/M&amp;A</span>
                    <span class="category-count">9 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-19">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-19 14:34</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Decision introduces zolbetuximab for eligible patients in NHS Scotland</p>
                    
                    <a href="https://pharmatimes.com/news/scottish-medicines-consortium-becomes-first-in-uk-to-adopt-new-precision-gastric-cancer-treatment/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AAX Biotech and Vascurie announce new neuro-oncology collaboration
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-20 12:41</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The collaboration will help to advance a pipeline of antibody candidates</p>
                    
                    <a href="https://pharmatimes.com/news/aax-biotech-and-vascurie-announce-new-neuro-oncology-collaboration/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-19">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-19 14:42</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Company prepares marketing submission after treatment shows strong efficacy</p>
                    
                    <a href="https://pharmatimes.com/news/nxera-pharma-reports-positive-results-from-phase-3-insomnia-trial-in-south-korea/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Sun Pharmaâ€™s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-21 12:13</span>
                        
                    </div>
                    
                    <p class="news-summary">More than 71% of patients treated with Unloxcyt achieved disease control</p>
                    
                    <a href="https://pharmatimes.com/news/sun-pharmas-unloxcyt-now-available-in-us-for-advanced-cutaneous-squamous-cell-carcinoma/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Peter Llewellyn-Davies
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-21 12:02</span>
                        
                    </div>
                    
                    <p class="news-summary">ARTCLINE appoints Peter Llewellyn-Davies as Chairman of its Supervisory Board</p>
                    
                    <a href="https://pharmatimes.com/appointments/peter-llewellyn-davies/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Venner Shipley announces opening of new Bristol office
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-20 12:42</span>
                        
                    </div>
                    
                    <p class="news-summary">The firm already has a number of offices across the UK and Europe</p>
                    
                    <a href="https://pharmatimes.com/news/venner-shipley-announces-opening-of-new-bristol-office/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Ipsen announces new data on Dysport in neurological disease
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-15 12:55</span>
                        
                    </div>
                    
                    <p class="news-summary">Dysport reduces muscle contractions by blocking the transmission of nerve impulses</p>
                    
                    <a href="https://pharmatimes.com/news/ipsen-announces-new-data-on-dysport-in-neurological-disease/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Jurgen Berendsen
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-15 12:54</span>
                        
                    </div>
                    
                    <p class="news-summary">Symeres has appointed Jurgen Berendsen as Chief Financial Officer (CFO).</p>
                    
                    <a href="https://pharmatimes.com/appointments/jurgen-berendsen/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-15">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        True colours
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-15 10:09</span>
                        
                    </div>
                    
                    <p class="news-summary">The gold standard in spectroscopy</p>
                    
                    <a href="https://pharmatimes.com/web_exclusives/true-colours/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
        </main>

        <footer>
            <p>Generated by <strong>Pharma Daily</strong> - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ</p>
            <p>2026-01-22 03:46</p>
        </footer>
    </div>

    <script>
    (function() {
        // ========== Theme Switcher ==========
        const themeBtns = document.querySelectorAll('.theme-btn');
        const savedTheme = localStorage.getItem('pharma-daily-theme') || 'minimal';

        function setTheme(theme) {
            document.body.setAttribute('data-theme', theme);
            themeBtns.forEach(btn => {
                btn.classList.toggle('active', btn.getAttribute('data-theme') === theme);
            });
            localStorage.setItem('pharma-daily-theme', theme);
        }

        // Apply saved theme on load
        setTheme(savedTheme);

        themeBtns.forEach(btn => {
            btn.addEventListener('click', function() {
                setTheme(this.getAttribute('data-theme'));
            });
        });

        // ========== Date Filter ==========
        const filterBtns = document.querySelectorAll('.date-btn');
        const newsCards = document.querySelectorAll('.news-card');
        const filterCount = document.getElementById('filterCount');
        const categories = document.querySelectorAll('.category');

        function updateFilter(selectedDate) {
            let visibleCount = 0;

            newsCards.forEach(card => {
                const cardDate = card.getAttribute('data-date');
                if (selectedDate === 'all' || cardDate === selectedDate) {
                    card.classList.remove('hidden');
                    visibleCount++;
                } else {
                    card.classList.add('hidden');
                }
            });

            // Hide empty categories
            categories.forEach(category => {
                const visibleCards = category.querySelectorAll('.news-card:not(.hidden)');
                category.style.display = visibleCards.length > 0 ? 'block' : 'none';

                // Update category count
                const countSpan = category.querySelector('.category-count');
                if (countSpan) {
                    countSpan.textContent = visibleCards.length + ' æ¡';
                }
            });

            // Update filter count display
            if (selectedDate === 'all') {
                filterCount.textContent = '';
            } else {
                filterCount.textContent = `æ˜¾ç¤º ${visibleCount} æ¡æ–°é—»`;
            }
        }

        filterBtns.forEach(btn => {
            btn.addEventListener('click', function() {
                filterBtns.forEach(b => b.classList.remove('active'));
                this.classList.add('active');
                updateFilter(this.getAttribute('data-filter'));
            });
        });
    })();
    </script>
</body>
</html>